Global Blood Therapeutics has assembled a team of employees, directors and scientific founders rich in scientific experience and capabilities in drug discovery, development and commercialization. Our management has a successful track record in developing and commercializing drug candidates in a wide range of therapeutic areas. We intend to leverage this expertise and experience to further advance our development pipeline.
President and Chief Executive Officer
Dr. Love joined GBT in June 2014 as president and chief executive officer with broad leadership and management experience in the biotech/pharmaceutical industry. Before that, he was executive vice president, research and development and technical operations at Onyx Pharmaceuticals, Inc., where he played an instrumental role in initiating and completing several of Onyx’s first Phase 3 clinical trials. Prior to Onyx, Dr. Love served as president, chief executive officer and chairman of Nuvelo, Inc., where he led growth of the company to a market capitalization of $1 billion. Prior to that, he served as senior vice president, development at Theravance, Inc. Earlier in his career, Dr. Love held a number of senior management positions in medical affairs and product development at Genentech, where he served as chairman of Genentech’s Product Development Committee. As vice president, product development, Dr. Love oversaw the development strategy and execution leading to approvals of Rituxan®, Herceptin®, Xolair®, TNKase®, Raptiva and Avastin®. Dr. Love has served as a consultant in medicine in the Department of Cardiology at the Massachusetts General Hospital. He currently serves on the board of directors of Amicus Therapeutics, Inc. Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.
Chief Business and Strategy Officer
Ms. Choi joined GBT in April 2015 as chief business and strategy officer. She is responsible for spearheading the company’s business development activities and corporate strategy, including identifying and executing strategic transactions to drive corporate value. She also oversees patient advocacy activities. During her career, Ms. Choi has led or managed over 50 transactions exceeding $13 billion in value. Prior to GBT, she served as senior vice president, corporate development for InterMune, Inc., a biotechnology company acquired by Roche Holding AG, and served as an adviser on strategy and business development. Before that, Ms. Choi led corporate and business development for Chimerix, Inc. as a consultant and senior vice president, corporate development. Prior to that, she held various management positions at Gilead Sciences, Inc., including leadership of business development, licensing and mergers and acquisition activities. During her tenure at Gilead, she built and oversaw the corporate development group and led the U.S. commercial launch of Hepsera® for the treatment of hepatitis B virus. She also has venture capital and strategy experience having served as a vice president at Bay City Capital and an engagement manager at McKinsey & Company. Ms. Choi received a B.A. in human biology and an M.B.A. from Stanford University.
Chief Financial Officer
Mr. Farrow joined GBT in April 2016 as chief financial officer with expertise in leading finance, risk management and investor relations for several public biotech companies as they evolved from discovery and development to commercial stage. Mr. Farrow previously served as chief financial officer of ZS Pharma, Inc., a biopharmaceutical company acquired by AstraZeneca. Prior to ZS Pharma, he served as chief financial officer at Hyperion Therapeutics, Inc., where he led Hyperion’s initial public offering and follow-on offering and was part of the team responsible for the successful regulatory approval and commercial launch of RAVICTI® for the treatment of urea cycle disorders. He previously served as vice president of finance at Evotec AG, a drug discovery and development company. Prior to Evotec, Mr. Farrow served as vice president of finance and chief accounting officer at Renovis, Inc., a drug discovery and development company acquired by Evotec AG. Earlier in his career, Mr. Farrow worked in the audit practice of KPMG LLP. Mr. Farrow holds a B.A. in business administration with a concentration in corporate finance from California State University at Fullerton. He is a certified public accountant (inactive).
Chief Commercial Officer
Mr. Johnson joined GBT in March 2018 as chief commercial officer. He is responsible for creating and leading the company’s commercial operations, including building and leading sales, marketing, business analytics and market access. Prior to GBT, Mr. Johnson spent 15 years at Gilead Sciences, Inc. in roles of increasing responsibility. Most recently, he served as vice president, sales and marketing, Liver Disease Business Unit, where he was responsible for the company’s liver disease franchises. He was instrumental in the commercial launches of the hepatitis C treatments Sovaldi®, Harvoni®, Epclusa® and Vosevi®, and the hepatitis B treatment Vemlidy®. Prior to that position, he was vice president, sales and marketing, for Gilead’s Antiviral Business Unit, where he launched the HIV treatments Complera® and Stribild®. Prior to joining Gilead, Mr. Johnson had an 11-year tenure at Glaxo Smith Kline, where he held various positions in sales, product marketing, business development, global commercial strategy and portfolio development. He received a B.A. in business marketing from the University of Puget Sound and an M.B.A. from the Kenan-Flagler Business School at the University of North Carolina.
Chief Legal Officer
Ms. Suvari joined GBT in October 2016 as chief legal officer with extensive experience in the life sciences industry. Previously, she served in several senior roles at CV Therapeutics, Inc. (which was acquired by Gilead Sciences, Inc.), ultimately as senior vice president, general counsel and chief compliance officer. In that position, she led the in-house legal team as the company transitioned from an R&D-stage company to a commercial-stage company with marketed products in the U.S. and EU and multiple partnering arrangements. Prior to CV Therapeutics, she served as corporate counsel at Genentech, Inc. in increasingly senior roles where she completed many complex business development and licensing transactions and advised on legal compliance for several commercial products. Before joining GBT, Ms. Suvari served as a vice president and general counsel at the non-profit Peninsula Open Space Trust. She has also served as an independent consultant supporting early-stage private and public biopharmaceutical companies. Ms. Suvari earned a B.S. in geology and geophysics from Yale University and a J.D. from Harvard Law School.
Senior Vice President, Development
Dr. Lehrer joined GBT in October 2013 as medical director and was appointed senior vice president, development in July 2017. At GBT, he has overseen the clinical development organization and has led program strategy and execution for voxelotor (GBT440), bringing it through early stage studies into a pivotal Phase 3 program in sickle cell disease. Prior to GBT, Dr. Lehrer led clinical development programs through proof of concept at Genentech in multiple indications and held key roles in business development and overseeing cardiovascular safety. Dr. Lehrer has served as adjunct faculty in the Division of Cardiology at Stanford School of Medicine. Dr. Lehrer holds an AB from Harvard College in Biochemistry and an M.Phil. in Biological Sciences from Cambridge University. Dr. Lehrer completed medical school and training in internal medicine at the University of California San Francisco (UCSF) and cardiology specialty training and postdoctoral research at Stanford University School of Medicine.
Senior Vice President, Operations
Mr. Radovich joined GBT in November 2014 as vice president, program leadership and business strategy and was appointed senior vice president, operations in September 2016. He is responsible for the Company’s program management, technical operations, commercial strategy and quality assurance functions. Prior to joining GBT, he served as vice president of program leadership at Onyx Pharmaceuticals, Inc., which was acquired by Amgen, Inc. Before that, he was senior director at Onyx, where he led the company’s global, cross-functional product team responsible for the development and commercialization of Kyprolis®. Prior to that, he held a variety of roles of increasing responsibility in Onyx’s commercial organization supporting Kyprolis and Nexavar® and was a key member of the deal team for Onyx’s acquisition of Proteolix. Prior to Onyx, he was at Chiron Corporation (now Novartis AG) in product marketing supporting Proleukin® (interleukin-2) in multiple oncology indications. Mr. Radovich holds a B.A. in biology and chemistry from Texas Christian University and an M.B.A. from Washington University.
Senior Vice President, Medical and Regulatory Affairs
Dr. Jonathan Sorof joined GBT in July 2017 as Senior Vice President, Medical and Regulatory affairs. Prior to joining the biotech/pharmaceutical industry, Jonathan spent 9 years in Academic clinical practice at the Texas Medical Center in Houston pursuing NIH-funded clinical research in pediatric cardiovascular disease. Prior to joining GBT, Jonathan spent 15 years at AstraZeneca and Genentech/Roche where he held various US and Global positions, including US Therapeutic Area Head for Cardiovascular and Metabolic Diseases, Global Head of Pediatric Oncology Regulatory Affairs, and most recently as Global Therapeutic Area Head for Immunology, Respiratory, & Ophthalmology based in Basel, Switzerland. Whilst at AstraZeneca and Genentech, Jonathan leveraged his pediatric experience in the design, execution and completion of multiple pediatric clinical trials, resulting in successful negotiations with the FDA for updated pediatric labeling for several marketed products and for innovative clinical development strategies for pediatric rare diseases. He has also led multiple teams preparing for product launches in US and Rest of World in a variety of therapeutic areas. He received his M.D degree from University of Pennsylvania School of Medicine, trained in Pediatrics at Children's National Medical Center in Washington DC, and in Pediatric Nephrology at UCSF.
Vice President, Human Resources
Mr. Krause joined GBT in March 2014 as senior director, human resources, and was appointed vice president, human resources, in February 2018. Prior to GBT, he served as senior director of human resources at Amyris Biotechnologies. Prior to that, Mr. Krause served as senior director of human resources at CV Therapeutics, Inc. (which was acquired by Gilead Sciences, Inc.), where he helped grow the organization from approximately 150 to nearly 700 employees, including the buildout of its commercial organization for the launch of Ranexa. Earlier in his career, he held roles at Gilead Sciences and Bio-Rad Laboratories. Mr. Krause earned a B.S. in business administration with a concentration in finance from California State University, Long Beach and an M.S. in industrial relations from the University of Oregon.
Vice President, Investor Relations and Corporate Communications
Ms. Lacy joined GBT in April 2016 as senior director, investor relations and corporate communications, and was appointed vice president, investor relations and corporate communications, in February 2018. She is responsible for the company’s strategy and execution of communications to employees, investors and media. Prior to joining GBT, she served as senior director of investor relations and corporate communications at ZS Pharma. Before that, Ms. Lacy served as director of investor relations and corporate communications at Hyperion Therapeutics. Earlier in her career, she held positions at Elan, Cerus, Tercica, InterMune and Chiron. Ms. Lacy earned a B.A. in business communications from Holy Names University.